Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note issued to investors on Thursday,Benzinga reports. D. Boral Capital currently has a $5.00 price objective on the stock.

A number of other analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hoth Therapeutics in a report on Monday, December 1st. Wall Street Zen cut Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.50.

Hoth Therapeutics Price Performance

Hoth Therapeutics stock opened at $1.20 on Thursday. Hoth Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $3.80. The firm has a fifty day moving average price of $1.35 and a two-hundred day moving average price of $1.33. The firm has a market cap of $18.62 million, a price-to-earnings ratio of -1.13 and a beta of 0.64.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.20). As a group, sell-side analysts expect that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Institutional Trading of Hoth Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of HOTH. Citadel Advisors LLC bought a new position in Hoth Therapeutics in the third quarter worth $232,000. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics in the 3rd quarter valued at $184,000. Kestra Private Wealth Services LLC acquired a new position in shares of Hoth Therapeutics in the 3rd quarter valued at $51,000. Lido Advisors LLC bought a new position in shares of Hoth Therapeutics during the 3rd quarter worth about $32,000. Finally, Geode Capital Management LLC boosted its position in shares of Hoth Therapeutics by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares in the last quarter. 7.08% of the stock is currently owned by institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.